56 related articles for article (PubMed ID: 20501913)
1. Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials.
Cho SY; Ohnuma T; Silverman LR; Holland JF; Roboz J
Drug Metab Dispos; 2010 Sep; 38(9):1480-5. PubMed ID: 20501913
[TBL] [Abstract][Full Text] [Related]
2. Investigation of suramin-albumin binding by electrospray mass spectrometry.
Roboz J; Deng L; Ma L; Holland JF
Rapid Commun Mass Spectrom; 1998; 12(19):1319-22. PubMed ID: 9773522
[TBL] [Abstract][Full Text] [Related]
3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
5. Intact human holo-transferrin interaction with oxaliplatin.
Zhao YY; Mandal R; Li XF
Rapid Commun Mass Spectrom; 2005; 19(14):1956-62. PubMed ID: 15954173
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins.
Rudnev AV; Foteeva LS; Kowol C; Berger R; Jakupec MA; Arion VB; Timerbaev AR; Keppler BK
J Inorg Biochem; 2006 Nov; 100(11):1819-26. PubMed ID: 16938349
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro.
Olsen H; Andersen A; Nordbø A; Kongsgaard UE; Børmer OP
BMC Clin Pharmacol; 2004 Mar; 4():4. PubMed ID: 15046641
[TBL] [Abstract][Full Text] [Related]
8. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
Zandvliet AS; Copalu W; Schellens JH; Beijnen JH; Huitema AD
Drug Metab Dispos; 2006 Jun; 34(6):1041-6. PubMed ID: 16565173
[TBL] [Abstract][Full Text] [Related]
9. Epitope mapping and competitive binding of HSA drug site II ligands by NMR diffusion measurements.
Lucas LH; Price KE; Larive CK
J Am Chem Soc; 2004 Nov; 126(43):14258-66. PubMed ID: 15506793
[TBL] [Abstract][Full Text] [Related]
10. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
[TBL] [Abstract][Full Text] [Related]
11. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.
Weigand M; Hartung G; Roboz J; Sieger S; Wolf M; Sinn H; Schrenk HH; Wiessler M; Frei E
Anticancer Drug Des; 2001; 16(4-5):227-37. PubMed ID: 12049481
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
Rowley M; Kulagowski JJ; Watt AP; Rathbone D; Stevenson GI; Carling RW; Baker R; Marshall GR; Kemp JA; Foster AC; Grimwood S; Hargreaves R; Hurley C; Saywell KL; Tricklebank MD; Leeson PD
J Med Chem; 1997 Dec; 40(25):4053-68. PubMed ID: 9406596
[TBL] [Abstract][Full Text] [Related]
14. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.
Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F
Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
Park IW; Reddy MV; Reddy EP; Groopman JE
Oncogene; 2007 Aug; 26(38):5635-42. PubMed ID: 17369860
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
17. Infusion of albumin attenuates changes in serum protein binding of drugs in surgical patients compared with volume replacement with HAES.
Reine PA; Kongsgaard UE; Andersen A; Thøgersen AK; Olsen H
Acta Anaesthesiol Scand; 2008 Mar; 52(3):406-12. PubMed ID: 18269390
[TBL] [Abstract][Full Text] [Related]
18. The properties of slightly soluble Zn(II)-protein complexes in the form of a suspension.
Dolińska B; Ryszka F
Farmaco; 2005 Jan; 60(1):71-5. PubMed ID: 15652372
[TBL] [Abstract][Full Text] [Related]
19. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
20. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
